Citi: Lowered the target price of XINYI GLASS (00868) to HKD 10.3. Mid-term performance exceeded expectations, but cost pressures increase in the second half.
The bank has raised its company's profit forecast for this year by 1%, but has lowered the forecast for 2027 to 2028 by 2% to reflect the pressure on gross margins starting in the second half of this year.
Citibank released a research report stating that XINYI GLASS (00868) exceeded market expectations in terms of revenue, gross margin, and net profit in the first half of the year. However, the bank anticipates that cost pressures will be more significant in the second half of the year, thus lowering its target price from HKD 11.7 to HKD 10.3 while maintaining a "neutral" rating. The report mentioned that XINYI GLASS's revenue fell 3% year-on-year, which is 2% higher than market expectations; the gross margin was 30.1%, down 1.5 percentage points year-on-year, but 1.2 percentage points higher than market forecasts; the net profit increased by 17% year-on-year, exceeding market expectations by 18%. In response to a decline in capital expenditure, the bank raised its net profit forecast for the company for this year by 1%, but reduced the forecasts for 2027-28 by 2% to reflect the gross margin pressure starting in the second half of this year.
Related Articles

HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 3% as the phase II clinical research of WeiliXin for the first-line treatment of hepatocellular carcinoma successfully entered the expansion phase.

HK Stock Market Move | APEX ACE HLDG (06036) surged over 18% during trading, expecting the net profit attributable to shareholders for the first half of the year to grow to HKD 130 million to HKD 140 million compared to the same period last year.

HK Stock Market Move | The decline in storage concepts is significant, and the revenue guidance from US storage giants falls short of expectations, resulting in a transmission of sluggish sentiment to the Asia-Pacific market.
HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 3% as the phase II clinical research of WeiliXin for the first-line treatment of hepatocellular carcinoma successfully entered the expansion phase.

HK Stock Market Move | APEX ACE HLDG (06036) surged over 18% during trading, expecting the net profit attributable to shareholders for the first half of the year to grow to HKD 130 million to HKD 140 million compared to the same period last year.

HK Stock Market Move | The decline in storage concepts is significant, and the revenue guidance from US storage giants falls short of expectations, resulting in a transmission of sluggish sentiment to the Asia-Pacific market.

RECOMMEND





